TABLE 1.
The drug-resistance of NCI-H460/TPT10 and the reversal effect with cabozantinib.
| Treatment | IC50 ± SDa (μM; Resistance foldb) | |
| NCI-H460 | NCI-H460/TPT10 | |
| Topotecan | 0.0476 ± 0.0042 (1.00) | 10.1044 ± 0.9571 (212.39)* |
| +CBZ 3 μM | 0.0468 ± 0.0041 (0.98) | 0.0883 ± 0.0072 (1.86) |
| +CBZ 5 μM | 0.0287 ± 0.0022 (0.60) | 0.0449 ± 0.0024 (0.94) |
| +Ko143 5 μM | 0.0292 ± 0.0027 (0.61) | 0.0401 ± 0.0042 (0.84) |
| Mitoxantrone | 0.0363 ± 0.0043 (1.00) | 4.2621 ± 0.5715 (117.36)* |
| +CBZ 3 μM | 0.0391 ± 0.0022 (1.08) | 0.0554 ± 0.0188 (1.53) |
| +CBZ 5 μM | 0.0376 ± 0.0012 (1.04) | 0.0373 ± 0.0031 (1.03) |
| +Ko143 5 μM | 0.0325 ± 0.0028 (0.90) | 0.0302 ± 0.0042 (0.83) |
| SN-38 | 0.0112 ± 0.0020 (1.00) | 1.3125 ± 0.1991 (116.96)* |
| +CBZ 3 μM | 0.0131 ± 0.0015 (1.17) | 0.0385 ± 0.0052 (3.44) |
| +CBZ 5 μM | 0.0139 ± 0.0022 (1.24) | 0.0129 ± 0.0044 (0.98) |
| +Ko143 5 μM | 0.0130 ± 0.0007 (1.16) | 0.0188 ± 0.0022 (1.68) |
| Cisplatin | 1.3750 ± 0.0908 (1.00) | 1.3575 ± 0.0409 (0.99) |
| +CBZ 3 μM | 1.3883 ± 0.0744 (1.01) | 1.3582 ± 0.0722 (0.99) |
| +CBZ 5 μM | 1.3514 ± 0.0591 (0.98) | 1.3952 ± 0.0642 (1.01) |
| +Ko143 5 μM | 1.3868 ± 0.0668 (1.01) | 1.3765 ± 0.0837 (1.00) |
aIC50: concentration that inhibited cell survival by 50% (mean ± SD). bResistance fold represents IC50 value for topotecan, mitoxantrone, SN-38, or cisplatin with or without CBZ or Ko143 divided by IC50 value for topotecan, mitoxantrone, SN-38, or cisplatin of NCI-H460 cells without CBZ or Ko143. Values in table are determined from at least three independent experiments performed in triplicate. *indicates significant difference from IC50 of NCI-H460/TPT10 (*P < 0.05).